Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VSJ 110

Next Previous
X
Search
Drug Profile

VSJ 110

Alternative Names: CFTRact-K267; VSJ-110

Latest Information Update: 11 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer Vanda Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Diamines; Eye disorder therapies; Fluorinated hydrocarbons; Small molecules; Triazines
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic conjunctivitis; Dry eyes

Most Recent Events

  • 29 Feb 2024 Phase-II clinical trials in Dry eyes in USA (Ophthalmic) (NCT06296966)
  • 26 Dec 2022 Phase-II development is ongoing in Allergic conjunctivitis in USA (Ophthalmic) (NCT04622345)
  • 28 Jun 2021 Vanda Pharmaceuticals completes phase II trial in Allergic conjunctivitis in USA (Ophthalmic) in June 2021 (NCT04622345)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top